Biocompatibility and IEC 60601: Mapping Test Reports to Chilean Standards

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Biocompatibility (ISO 10993 series) and medical electrical safety (IEC 60601 series) are the two core blocks of test evidence for active and body-contacting devices in Chile. How they apply is determined by Article 111(c) of the Sanitary Code: Chilean official standards (NCh) first; where no NCh standard exists, standards approved by the Ministry of Health based on information from international organizations or foreign specialized bodies.

GRZAN’s operational conclusion: the test reports themselves are usually acceptable; the critical task is building the three-layer mapping of report, NCh standard and 16142 essential principles, and stating the alternative basis in writing wherever an NCh standard is missing. Reports without a visible path to a Chilean-referenced standard generate queries even when the underlying testing is flawless. For components purchased rather than manufactured, the mapping is also where supplier statements and certificates of analysis plug into the dossier.

2. Legal basis

  • Sanitary Code | DFL N° 725, de 1967 | Article 111(c) | control and quality testing follow the Chilean official standards approved by the Ministry of Health on the proposal of the national standardization body (INN); where no such standards exist, the standards approved by the Ministry of Health apply, based on the ISP’s proposal and on information from international organizations or foreign specialized bodies.
  • Regulation on the control of pharmaceutical products and medical devices | Decreto Supremo N° 825, de 1998 | August 21, 1999 | Article 21(a), point 2: materials declaration (list of components and raw materials, chemical testing and biological evaluation); point 5: performance evaluation (against Chilean official standards, or against standards approved by the Ministry of Health where none exist).
  • Decree listing devices under the sanitary control regime of Article 111 | Decreto Exento N° 25, de 2026 | March 19, 2026 | conformity evaluation is benchmarked against NCh-ISO 16142-1 and 16142-2, NCh-ISO 13485, NCh-ISO 14971 and the product-specific standards listed in the annex; the listed categories include active equipment such as X-ray machines, CT scanners, radiotherapy equipment, mechanical ventilators and high-frequency electrosurgical units.
  • Decree bringing portable automated external defibrillators into scope | Decreto Supremo N° 42, de 2021 | 2021 | the precedent for controlled categories of existing active equipment.

3. Expert insights

Insight one: Article 21 writes biological evaluation into the Class I base layer.

The provision requires chemical testing and biological evaluation already within the six Class I dossier items. This means biocompatibility is not a privilege of high-risk devices: any device that contacts the human body must answer the materials safety question. The classes differ in depth, not in principle — the duration and nature of contact determine how many evaluation endpoints are required, but the obligation to address biological evaluation exists from the first rung of the ladder upward. The practical consequence is that materials questions belong in the project plan from day one, not in the final weeks before filing.

Insight two: the ISO 10993-1 contact categories must be aligned with the time thresholds of Article 2 of DS 825/1998.

Article 2, items 3 to 5, of DS 825/1998 provides three thresholds: 60 minutes (transient), 30 days (short-term) and more than 30 days (long-term). The selection of biological evaluation endpoints should follow the contact classification matching these thresholds, and the report should state the correspondence explicitly. When the reviewer can trace the endpoint selection back to a statutory threshold in one line, the file reads as deliberate; when the reader must infer it, queries follow.

Insight three: the IEC 60601 series must be organized in the three layers of general, collateral and particular.

Electrical safety evidence for active equipment normally consists of the general standard (IEC 60601-1), collateral standards such as electromagnetic compatibility, and particular standards for the specific equipment type. Exempt Decree No. 25/2026 brought in a large volume of active equipment — X-ray machines, CT scanners, radiotherapy equipment, ventilators, high-frequency electrosurgical units and manual defibrillator-monitors — and a missing layer in the three-layer structure will be queried. Confirm early whether a particular standard exists for the exact device type in the submission.

Insight four: the qualifications of the testing laboratory are an implicit review item.

Under a document review regime the ISP cannot repeat the tests, so it scrutinizes the traceability of the reports and the qualifications of the issuing laboratory. GRZAN recommends prioritizing reports from laboratories with the relevant accreditation, and retaining the original reports together with proof of the laboratory’s accreditation status. A well-accredited laboratory report answers, before it is asked, the question of why the ISP should believe the numbers on the page. Where accreditation is unavailable for a given test, a documented justification of the laboratory’s competence and the traceability of its methods should be prepared in advance.

4. Practical recommendations

  1. Build the three-layer mapping table: test report, then NCh standard, then NCh-ISO 16142 essential principles, aligned item by item.
  2. State the alternative basis in writing wherever an NCh standard is missing, invoking the hierarchy of Article 111(c) of the Sanitary Code.
  3. Determine the contact classification from the three time thresholds of Article 2 of DS 825/1998 — 60 minutes, 30 days, more than 30 days — and state it in the biological evaluation report.
  4. Organize IEC 60601 evidence in the general, collateral and particular layers, and verify that the particular standard covers the exact equipment type submitted.
  5. Retain the original test reports and the laboratory accreditation proof, so that verification queries can be answered quickly.

5. Verification checklist

  • □ The three-layer mapping of test report, NCh standard and 16142 principles is in place
  • □ A written alternative basis is stated for every item lacking an NCh standard (Article 111(c))
  • □ The biological evaluation endpoints follow the contact classification set by the 60 minutes and 30 days thresholds
  • □ The IEC 60601 general, collateral and particular reports are complete for active equipment
  • □ The original reports and the laboratory accreditation proof are retained

Regulatory information verified as of October 29, 2026.

For a product-specific feasibility assessment of Chile market entry, GRZAN’s regulatory team supports manufacturers and importers with registration dossiers, conformity documentation and ISP submissions. Contact info@grzanglobal.com to discuss your project.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail